NO20070876L - Apolipoprotein A1 mimetics og anvendelser derav. - Google Patents

Apolipoprotein A1 mimetics og anvendelser derav.

Info

Publication number
NO20070876L
NO20070876L NO20070876A NO20070876A NO20070876L NO 20070876 L NO20070876 L NO 20070876L NO 20070876 A NO20070876 A NO 20070876A NO 20070876 A NO20070876 A NO 20070876A NO 20070876 L NO20070876 L NO 20070876L
Authority
NO
Norway
Prior art keywords
apolipoprotein
mimetics
cholesterol levels
plasma cholesterol
useful
Prior art date
Application number
NO20070876A
Other languages
English (en)
Norwegian (no)
Inventor
William W Bachovchin
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of NO20070876L publication Critical patent/NO20070876L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20070876A 2004-07-16 2007-02-15 Apolipoprotein A1 mimetics og anvendelser derav. NO20070876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
PCT/US2005/025182 WO2006020040A2 (en) 2004-07-16 2005-07-15 Apolipoprotein a1 mimetics and uses thereof

Publications (1)

Publication Number Publication Date
NO20070876L true NO20070876L (no) 2007-03-30

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070876A NO20070876L (no) 2004-07-16 2007-02-15 Apolipoprotein A1 mimetics og anvendelser derav.

Country Status (12)

Country Link
US (3) US7569546B2 (enExample)
EP (1) EP1771473B1 (enExample)
JP (1) JP5048486B2 (enExample)
KR (1) KR101185609B1 (enExample)
CN (1) CN101076541A (enExample)
AU (1) AU2005275009B2 (enExample)
BR (1) BRPI0513402A (enExample)
CA (1) CA2574007A1 (enExample)
IL (1) IL180733A (enExample)
NO (1) NO20070876L (enExample)
TW (1) TWI377066B (enExample)
WO (1) WO2006020040A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EA200900786A1 (ru) * 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
CA2672131C (en) * 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
DK2396017T3 (en) 2009-02-16 2015-09-14 Cerenis Therapeutics Holding Sa Apolipoprotein A-I-mimetika
EP2582379A4 (en) * 2010-06-15 2013-12-04 Matthew C Lawyer COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS
HUE042314T2 (hu) * 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
CN105050614B (zh) 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
EP3273944B1 (en) * 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
TW202130652A (zh) 2017-01-19 2021-08-16 美國衛生與公眾服務部 Apoc-ii擬肽
EP4135747A1 (en) 2020-04-16 2023-02-22 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein- based complexes
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
EP4504150A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating eye diseases using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
RU2414236C2 (ru) * 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол

Also Published As

Publication number Publication date
CA2574007A1 (en) 2006-02-23
JP5048486B2 (ja) 2012-10-17
EP1771473A2 (en) 2007-04-11
WO2006020040A3 (en) 2006-07-06
BRPI0513402A (pt) 2008-05-06
IL180733A (en) 2013-01-31
IL180733A0 (en) 2007-06-03
TWI377066B (en) 2012-11-21
US20100009919A1 (en) 2010-01-14
US7569546B2 (en) 2009-08-04
JP2008506709A (ja) 2008-03-06
KR20070095862A (ko) 2007-10-01
US20120259091A1 (en) 2012-10-11
US8124580B2 (en) 2012-02-28
AU2005275009B2 (en) 2011-12-08
AU2005275009A1 (en) 2006-02-23
EP1771473B1 (en) 2012-12-26
TW200612977A (en) 2006-05-01
US20060069030A1 (en) 2006-03-30
KR101185609B1 (ko) 2012-09-24
WO2006020040A2 (en) 2006-02-23
CN101076541A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
NO20070876L (no) Apolipoprotein A1 mimetics og anvendelser derav.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2008013589A3 (en) Treatment of ras-expressing tumors
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
WO2007092622A3 (en) Compositions and methods for treating bone
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
DK1984357T3 (da) 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
PL2207786T3 (pl) 2'-fluoro-2'-deoksy tetrahydrouryny jako inhibitory dezaminazy cytydyny
NO20073105L (no) Pyridazinonforbindelser
EP2021797A4 (en) N-2,2,4-bis (1,1-dimethylethyl) -5-hydroxy-phenyl-1,4-dihydro-4-oxoquinol-3-carboxamide
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
TW200736253A (en) Pyridopyrazine derivatives and their use
NO20082075L (no) Anti-hyperkolesterolemiske forbindelser
NO20082497L (no) Diarylureaer for behandling av pulmonal hypertensjon
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MX2009007911A (es) Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.
NO20091353L (no) Serine hydrolaseinhibitorer
NO20071510L (no) 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser
WO2008013983A3 (en) Opsin stabilizing compounds and methods of use
BRPI0622083A2 (pt) Método e aparelho destinados à fabricação de substratos purificados ou substratos puros que são adicionalmente processados.
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application